Emerging Stocks Down Under 6 September 2022: Medlab Clinical (ASX:MDC)
Medlab Clinical: Too many downside risksMedlab Clinical (ASX: MDC) is one of the most unique biotechs on the ASX. It is rare to have a company that has advanced a treatment to Phase 3 and even more so for a company that has a cannabis-based treatment, but Medlab has done this. Still, it has not eliminated all uncertainty surrounding itself, including funding and a potential listing on NASDAQ. Click here to read the previous edition of Emerging Stocks Down Under published 30 August 2022. For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.